Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pan-FGFR inhibitor ABSK-121-NX

An orally bioavailable, small molecule pan-inhibitor of fibroblast growth factor receptor (FGFR) family proteins, with potential antineoplastic activity. Upon oral administration, pan-FGFR inhibitor ABSK-121 binds to and inhibits FGFR family proteins, including FGFR2 and FGFR3 gatekeeper, molecular brake, and activation loop mutations. This prevents FGFR-mediated signaling, and inhibits both tumor angiogenesis and proliferation of FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, cell survival and angiogenesis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:FGFR inhibitor ABSK-121
pan-fibroblast growth factor receptor inhibitor ABSK-121
Code name:ABSK 121
ABSK-121
ABSK-121-NX
ABSK121
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search